TABLE 3.
Visual Acuities and Macular Thicknesses at Baseline and Follow-up Visits for Patients with Choroidal Neovascularization
| Visit | Median BCVA (range) | Number of Eyes |
P valuea | Mean Central Subfield Thicknessb ± SD μm (range) |
Number of Eyes |
P valuec |
|---|---|---|---|---|---|---|
| Baseline | 20/80 (20/20 to HM) | 21 | — | 292 ± 114 (157 to 592) | 19 | — |
| Month 1 | 20/40 (20/20 to CF) | 19 | .034 | 249 ± 65 (162 to 389) | 17 | .12 |
| Month 3 | 20/60 (20/70 to 20/300) | 14 | .84 | 285 ± 84 (84 to 437) | 12 | .27 |
| Month 6 | 20/50 (20/25 to 4/200) | 12 | .67 | 264 ± 55 (187 to 333) | 9 | .35 |
| Month 12 | 20/60 (20/20 to 20/300) | 6 | .23 | 220 ± 29 (202 to 271) | 5 | .44 |
BCVA = best-corrected visual acuity; CF = count fingers; HM = hand motion; SD = standard deviation.
a
P value comparing baseline to follow-up BCVA (Wilcoxon signed-rank test).
b
Measured by optical coherence tomography.
c
P value comparing baseline to follow-up central subfield thickness (paired t test).